Adrenomedullin and Outcome in Severe Sepsis and Septic Shock

Overview

The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings concerning the association of ADM concentration and the use of vasopressor therapy, organ failure and outcome.

Full Title of Study: “Adrenomedullin and Outcome in Severe Sepsis and Septic Shock. The AdrenOSS Study.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2016

Detailed Description

Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise vascular integrity and cause tissue edema, organ dysfunction and death. Adrenomedullin (ADM) has attracted the interest of researchers because of its powerful physiological functions. An anti-ADM antibody reduced the norepinephrine infusion rates required to achieve hemodynamic targets, increased urine flow and improved creatinine clearance, which ultimately resulted in attenuated systemic inflammation and tissue apoptosis, during resuscitated cecal ligation and puncture (CLP)-induced septic shock in mice. In humans, plasma ADM has been determined only in a small number of sepsis patients, and - except from one study – the assays used did not selectively measure the bioactive ADM form and have been considered not reliable. Therefore, the potential value of determining plasma ADM in such patients cannot yet be ascertained and the optimal cut off needs to be validated in future studies

Clinical Trial Outcome Measures

Primary Measures

  • rate of all-cause mortality
    • Time Frame: Day 28.

Participating in This Clinical Trial

Inclusion Criteria

  • Age >18 years – Patients admitted in intensive care unit for severe sepsis or septic shock according to international, standardized criteria,transferred from another intensive care unit less than 24 hours after the primary admission, or being treated with vasopressors for less than 24 hours in the prior ICU – Signed Consent form Exclusion Criteria:

  • Age < 18 years – Severe sepsis or septic shock patients transferred from another intensive care unit later than 24 hours after the primary admission or being treated with vasopressors for more than 24 hours in the prior ICU – Pregnant women – Vegetative coma – Participation in an interventional clinical trial in the preceding month

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sphingotec GmbH
  • Collaborator
    • Fondation Transplantation_EDDH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alexandre Mebazaa, Pr, Principal Investigator, Hôpital Lariboisière, France
    • Pierre François Laterre, Pr, Principal Investigator, Clinique Universitaire St Luc, Belgique

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.